ACR open rheumatology · 2025
Tumor Necrosis Factor Inhibitor Therapy Increases Absolute Lymphocyte Count and Is Associated With Lower Mortality in Patients With Psoriatic Arthritis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kostadinova Lenche, Wilson Brigid, Siddiqui Hinnah, Behrens Sara, Gupta Angela, O'Mara Megan, Brittlebank Jemima, Nahra Vicky, Makandura Mahesha, Malakooti Shahdi K, Hall Eric, Silversteyn Laura, Shive Carey L, Mattar Maya, Zidar David A, Anthony Donald D
Аннотация
OBJECTIVE: Pathogenic inflammation in psoriatic arthritis (PsA) includes tumor necrosis factor (TNF) signaling. We observed that lower absolute lymphocyte count (ALC) was associated with greater mortality in persons with rheumatoid arthritis, and the start of TNF inhibitor (TNFi) therapy was associated with increased ALC. The effect of TNFi on ALC and mortality in PsA is not known.
METHODS: Using the VA Corporate Data Warehouse, we identified patients with PsA that initiated TNFi in 2010 through 2015 with laboratory tests before and 3 to 24 months after therapy initiation. Patients with PsA seen in rheumatology clinics were matched by age, sex, race and ethnicity with controls. In a subset of local patients and controls, we evaluated markers of inflammation and other correlates of ALC.
RESULTS: Among 1923 patients with PsA, ALC increased by a mean of 0.22 × 103 cell/μL (95% confidence interval [CI] = 0.20, 0.25) following TNFi initiation, whereas in controls, there was minimal change in ALC (0.01 × 103 cell/μL, 95% CI = 0.00, 0.02). Survival curves differed significantly among patients with PsA with baseline ALC above 1.2 × 103 cell/μL, below 1.2 × 103 cell/μL that remained low after start of TNFi, and below 1.2 × 103 cell/μL that increased to above 1.2 × 103 cell/μL with therapy. Higher ALC at baseline and increased ALC at follow-up were associated with higher subsequent survival. Local cohort analysis indicated lower circulating T cell effector and terminal effector memory frequencies in PsA that positively correlated with ALC. Patients with PsA treated with TNFi had lower interleukin-6 (IL-6) levels that negatively correlated with ALC.
CONCLUSION: TNFi therapy increases the peripheral blood ALC in patients with PsA, and this is associated with lower subsequent mortality. Mechanisms underlying this relationship may include effects of PsA, TNFi, and IL-6 on T cell subset homeostasis.
METHODS: Using the VA Corporate Data Warehouse, we identified patients with PsA that initiated TNFi in 2010 through 2015 with laboratory tests before and 3 to 24 months after therapy initiation. Patients with PsA seen in rheumatology clinics were matched by age, sex, race and ethnicity with controls. In a subset of local patients and controls, we evaluated markers of inflammation and other correlates of ALC.
RESULTS: Among 1923 patients with PsA, ALC increased by a mean of 0.22 × 103 cell/μL (95% confidence interval [CI] = 0.20, 0.25) following TNFi initiation, whereas in controls, there was minimal change in ALC (0.01 × 103 cell/μL, 95% CI = 0.00, 0.02). Survival curves differed significantly among patients with PsA with baseline ALC above 1.2 × 103 cell/μL, below 1.2 × 103 cell/μL that remained low after start of TNFi, and below 1.2 × 103 cell/μL that increased to above 1.2 × 103 cell/μL with therapy. Higher ALC at baseline and increased ALC at follow-up were associated with higher subsequent survival. Local cohort analysis indicated lower circulating T cell effector and terminal effector memory frequencies in PsA that positively correlated with ALC. Patients with PsA treated with TNFi had lower interleukin-6 (IL-6) levels that negatively correlated with ALC.
CONCLUSION: TNFi therapy increases the peripheral blood ALC in patients with PsA, and this is associated with lower subsequent mortality. Mechanisms underlying this relationship may include effects of PsA, TNFi, and IL-6 on T cell subset homeostasis.